On October 15, 2019 Vigeo Therapeutics, a clinical-stage biopharmaceutical company developing novel therapeutics to reprogram the tumor immune microenvironment (TIME), reported that Jing Watnick, president and chief executive officer, will present at the BIO Investor Forum on Wednesday, October 23, 2019 at 10:00 am PT at the Westin St. Francis in San Francisco (Press release, Vigeo Therapeutics, OCT 15, 2019, View Source [SID1234542285]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the session will be streaming here and accessible through the "News" page of Vigeo’s website. A replay of the webcast will be archived on the Company’s website for 30 days following the presentation.

About VT1021
Vigeo’s lead molecule, VT1021, is a small peptide agent derived from prosaposin (Psap) that triggers Tsp-1 production, which in turn reprograms the tumor microenvironment and makes it inhospitable for tumor growth. Pre-clinical results have demonstrated that VT1021, when administered systemically, can cause tumor regression in animal models at both the primary and metastatic sites. VT1021 is currently being evaluated in a Phase 1, open label, multicenter trial that assesses the drug’s safety, tolerability, and preliminary anti-tumor efficacy. The trial’s dose escalation phase was launched in late 2017, and the expansion phase will begin in the fourth quarter of 2019. An interim readout is expected in the second half of 2020.

On October 15, 2019 OncoSec Medical Incorporated ("OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, reported the publication of new data in Clinical Cancer Research which highlighted TAVO (intratumoral plasmid IL-12 with electroporation) as a safe, feasibility and clinically meaningful therapy in patients with Merkel cell carcinoma (MCC), an aggressive form of skin cancer (Press release, OncoSec Medical, OCT 15, 2019, View Source [SID1234542267]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These data demonstrate that intratumoral delivery of plasmid interleukin-12 with electroporation (TAVO) as a monotherapy has the potential to have a durable impact on skin cancers such as Merkel cell carcinoma. I’m encouraged by these initial findings and believe that TAVO is a treatment approach that merits further exploration in MCC," commented Shailender Bhatia, M.D., associate professor, medical oncology, Department of Medicine, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, Washington and lead investigator and author of the study.

The single-arm, open label pilot study evaluated 15 patients with MCC receiving TAVO intratumorally in two cohorts (Cohort A N=3 and Cohort B N=12). Cohort A patients had locoregional MCC and received one treatment cycle prior to a definitive surgery. Cohort B patients had metastatic MCC and received four cycles of TAVO. Results showed that 25% of Cohort B patients experienced an overall response, with two patients receiving durable effect over 16 and 55+ months, respectively. Two Cohort A patients (one with pathologic complete remission) were recurrence-free at 44+ and 75+ months.

"We continue to explore the broad therapeutic potential of TAVO across various cancer types and believe this study underscores the power of TAVO monotherapy in solid tumors such as MCC," said Daniel J. O’Connor, president and chief executive officer of OncoSec. "We remain encouraged by the growing body of clinical evidence for TAVO in multiple cancer indications both as a monotherapy and in combination with leading checkpoint inhibitors. We look forward to providing further data updates as we continue to advance our ongoing pivotal clinical trial with TAVO in metastatic melanoma and our phase 2 trial in triple negative breast cancer."

An online version of the publication is available here: View Source

On October 15, 2019 Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, reported that the Company will present at the MicroCap Rodeo on Oct 16th at 9:45-10:15 AM in room 416B (Press release, Citius Pharmaceuticals, OCT 15, 2019, View Source [SID1234542286]). The conference is being held at the Hilton Austin in Austin, Texas on October 15-16, 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Leonard Mazur, Chairman, of Citius Pharmaceuticals will be delivering a presentation, as well as answering questions from investors. Earlier in the month, Citius Pharmaceuticals, reached the interim analysis milestone for Mino-Lok Phase III pivotal trial. To access Citius Pharmaceuticals live webcast please use the following link: View Source

Citius Pharmaceuticals, Inc. will also be available for one-on-one meetings. To arrange a meeting with the Company, please contact Mr. Andrew Scott: [email protected].

About MicroCap Rodeo

Bucking the trend of microcap conferences is the first-annual MicroCap Rodeo in Austin, Texas. This year’s theme: Lassoing the "Best Ideas."

Over two days in October, investors can harness top stocks for their portfolios. They’ll meet with executive management teams from approximately 50-plus microcap companies across a wide variety of industries and gain an understanding into the key value drivers and potential trends for 2020. Complementing the interactive, in-depth 30-minute one-on-one meeting format will be four tracks of company presentations.

When they’re not wrangling great ideas, investors can dig into delicious Texas food, entertainment and surprise guests.

On October 15, 2019 Genmab A/S (Nasdaq: GMAB) reported that worldwide net sales of DARZALEX (daratumumab) as reported by Johnson & Johnson were USD 765 million in the third quarter of 2019 (Press release, Genmab, OCT 15, 2019, View Source [SID1234542250]). Net sales were USD 402 million in the U.S. and USD 363 million in the rest of the world. Genmab will receive royalties on the worldwide net sales of DARZALEX under the exclusive worldwide license to Janssen Biotech, Inc. to develop, manufacture and commercialize DARZALEX.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

About DARZALEX(daratumumab)
DARZALEX (daratumumab) intravenous infusion is indicated for the treatment of adult patients in the United States: in combination with bortezomib, thalidomide and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI); and as a monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a PI and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.1 DARZALEX is the first monoclonal antibody (mAb) to receive U.S. Food and Drug Administration (U.S. FDA) approval to treat multiple myeloma. DARZALEX is indicated in Europe in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; and as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a PI and an immunomodulatory agent and who have demonstrated disease progression on the last therapy. The option to split the first infusion of DARZALEX over two consecutive days has been approved in both Europe and the U.S. In Japan, DARZALEX is approved in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adults with relapsed or refractory multiple myeloma and in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. DARZALEX is the first human CD38 monoclonal antibody to reach the market in the United States, Europe and Japan. For more information, visit www.DARZALEX.com.

Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. Daratumumab triggers a person’s own immune system to attack the cancer cells, resulting in rapid tumor cell death through multiple immune-mediated mechanisms of action and through immunomodulatory effects, in addition to direct tumor cell death, via apoptosis (programmed cell death).1,2,3,4,5

Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab. A comprehensive clinical development program for daratumumab is ongoing, including multiple Phase III studies in smoldering, relapsed and refractory and frontline multiple myeloma settings. Additional studies are ongoing or planned to assess the potential of daratumumab in other malignant and pre-malignant diseases in which CD38 is expressed, such as amyloidosis, NKT-cell lymphoma and B-cell and T-cell ALL. Daratumumab has received two Breakthrough Therapy Designations from the U.S. FDA for certain indications of multiple myeloma, including as a monotherapy for heavily pretreated multiple myeloma and in combination with certain other therapies for second-line treatment of multiple myeloma.

On October 15, 2019 CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related diseases and extend healthy lifespan, reported that its Chief Executive Officer, Steven Engle, will present at the 2019 BIO Investor Forum, which is being held October 22-23 at the Westin St. Francis Hotel in San Francisco, CA (Press release, CohBar, OCT 15, 2019, View Source [SID1234542268]). The BIO Investor Forum explores investment trends and opportunities in life sciences, with a focus on venture-stage growth and emerging public companies as well as those poised to join the growth "watch list" in 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details:
Wednesday, October 23rd 11:15 AM PT
Westin St. Francis Hotel, Yorkshire conference room

Webcast: The presentation may be accessed via webcast at the scheduled time, or after the presentation, using the following link: CohBar Presentation.